This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / AB Science Masitinib US Patent
Business patent grant

AB Science Masitinib US Patent

Analysis based on 6 articles · First reported Jun 17, 2026 · Last updated Jun 17, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The granting of a US patent for masitinib by the United States — United States Patent and Trademark Office is a positive development for Science, as it secures intellectual property protection for a key drug in a market with unmet medical needs. This could lead to increased investor confidence and potential future revenue streams for Science, especially given the large patient population for metastatic castrate resistant prostate cancer.

Pharmaceuticals Biotechnology
Event Summary

Science, a pharmaceutical company, announced that the United States — United States Patent and Trademark Office has formally granted a patent for its lead compound, masitinib, for the treatment of metastatic castrate resistant prostate cancer (mCRPC). This new US patent (US 12,648,944) provides intellectual property protection for masitinib until May 2042, adding to existing coverage in Europe. Masitinib is positioned in combination with docetaxel for mCRPC patients eligible for chemotherapy, particularly those with low metastatic involvement. The patent is based on positive data from study AB12003, which showed significant progression-free survival benefits.

Entities Involved
govactor
United States — United States Patent and Trademark Office
The United States Patent Office formally granted the patent for masitinib, providing intellectual property protection for Science in the US market.
Importance 70.0 Sentiment 0.0
loc
Europe
Europe had previously granted IP coverage for masitinib, which is now complemented by the US patent.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.